Haemonetics Q2 revenue and adjusted EPS beat expectations

What happened

Haemonetics said fiscal second-quarter revenue and adjusted earnings per share both beat analyst expectations. For FY27, it raised reported and organic revenue growth guidance, lowered its adjusted operating-margin expansion guidance, and lifted its free-cash-flow conversion guidance.

Confirmed

Global impact / market context

Higher revenue growth expectations may support future sales, but lower operating-margin expansion guidance signals that costs could absorb more of that growth. Tariff refunds and a richer product mix helped gross margin, while personnel and freight costs raised expenses; capital spending also weighed on free cash flow.

Analyst inference

The quarter showed stronger sales and adjusted earnings than analysts expected, alongside mixed changes to the full-year outlook. Revenue growth and cash-conversion guidance improved, while operating-margin expansion expectations fell, suggesting that sales growth may not translate fully into operating profit as costs rise.

Analyst inference

What to watch

1. Check whether Haemonetics delivers FY27 reported revenue growth of 8–11% and organic growth of 6–9%, the higher targets stated in its updated outlook. Confirmed
2. Watch operating costs and product mix: higher personnel and freight costs could limit profit growth, while higher-margin products may help offset that pressure. Analyst inference
3. Track capital spending and working-capital timing, meaning when customer payments and supplier bills are settled, because both can change cash available and free cash flow. Analyst inference

Evidence

• Original source link unavailable